- conhecimento
Artigos &
publicações
Cardiotoxicity of monoclonal antibody-based therapies in breast cancer: a contemporary narrative review
Monoclonal antibody-based therapies have substantially improved outcomes in breast cancer, particularly through HER2-directed treatment strategies, but have also introduced important cardiovascular toxicities that require careful recognition and management. This...
Two-stage risk-reducing breast surgery with a synthetic matrix: a case report
Risk-reducing mastectomy is a well-established strategy for patients at high risk of developing breast cancer, particularly those with known genetic mutations. However, in women presenting with large breasts and significant ptosis, skin-reducing mastectomy with...
Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials
Neoadjuvant therapy (NAT) is standard treatment for triple-negative breast cancer (TNBC) but toxicity is a major concern. This study aimed to assess the incidence and risk of grade ≥3 adverse events (AEs) associated with NAT in non-metastatic TNBC. Methods:We...
Reoperation rates following breast-conserving surgery in a contemporary cohort
Breast-conserving surgery (BCS) followed by adjuvant radiotherapy is the standard of care for early-stage breast cancer. However, reoperations after BCS may compromise aesthetic outcomes, increase surgical complications, and cause psychological distress. This study...
Optimizing axillary lymph node management in early-stage HR+/HER2- breast cancer: Practical strategies for enhanced detection rates
Abemaciclib is a globally approved, standard-of-care adjuvant treatment for HR+/HER2-high-risk EBC which significantly improved outcomes in combination with ET, versus ET alone, in the pivotal monarchE trial. Nodal involvement is a major adverse prognostic factor in...